Antares Pharma Inc

Antares Pharma — Investor Presentation (March 2020)

27 slides from Antares Pharma's investor presentation, Mar 4, 2020

  1. Slide 1: Antares Pharma Investor's Update March 2020

    Antares Pharma Investor’s Update March 2020 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements within the meaning of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those des

  3. Slide 3: Who We Are – A Pharmaceutical Technology Company

    At Antares Pharma, we leverage pharmaceutical and medical device expertise to develop innovative products that address needs in underserved therapeutic areas Who We Are – A Pharmaceutical Technology Company Our novel drug delivery technology can provide multiple product opportunities and life-cycle

  4. Slide 4: Antares Pharma Overview

    Antares Pharma is an innovative leader in self-administered injection technology We are a commercial, revenue-generating Company which develops combination products focused on rescue therapies Five products utilizing Antares devices were commercialized in the past six years. The three most recent: X

  5. Slide 5: Antares Pharma Snapshot: Dramatic growth in revenue

    Dramatic growth in revenue vs. prior years $92.1 M million in product revenue in 2019 – a 92% increase compared to the same period one year ago 2019 Proprietary Products Revenue: XYOSTED® and OTREXUP®: $39.2 M 2019 Partnered Products Revenue: Teva EpiPen Teva Sumatriptan Teva teriparatide Teva exena

  6. Slide 6: Rapidly Growing and Diversified Revenue Mix

    2019 Revenue Mix: $123.9M Rapidly Growing and Diversified Revenue Mix 2017 Revenue Mix: $54.5M

  7. Slide 7: 4-year Growth and 2020 Projection

    +95% vs. 2018 +17% vs. 2019* 4-year Growth and 2020 Projection* Projected CAGR of 29% * Percent increase based on midpoint of 2020 guidance +4% vs. 2016 $135 - $155

  8. Slide 8: Antares Pharma Proprietary Commercial Products

    Antares Pharma Proprietary Commercial Products March 2020

  9. Slide 9: XYOSTED: An innovative way to deliver testosterone replacement therapy

    An innovative way to deliver testosterone (T) replacement therapy 98.5% of patients in a 52-week phase-3 study achieved testosterone levels in the normal, physiologic range at week 12 A narrow peak-to-trough ratio of 1.8 T Levels maintained for as long as the patient stays on therapy* Steady, predic

  10. Slide 10: Ctrough Stable For Weeks

    Ctrough Stable For 52 Weeks 6 12 18 26 38 52 Week 1, pre-dose Mean Ctrough (ng/dL) over 52 week “003” study Green lines represent the defined range of 300 – 1100 ng/dL ………….. Baseline QST-13-003 treatment regimen demonstrated a mean steady state concentration of testosterone of 553.3 ± 127.3 ng/dL a

  11. Slide 11: XYOSTED Quarterly TRx Growth

    More than 62,000 XYOSTED TRx to date written by ~ 4,700 different physicians More than 15,000 patients prescribed XYOSTED since launch Q4 2019 TRx increased 42%* sequentially vs. Q319 As of October 1 2019 ~72% of all commercial lives covered XYOSTED® Quarterly TRx Growth 14,599 13,231

  12. Slide 12: Broad XYOSTED Utilization Across all Specialties

    Commercial Experience Broad XYOSTED® Utilization Across all Specialties* *Q419 IQVIA Data

  13. Slide 13: Multiple Channels Directed at Key XYOSTED Targets

    Trial Experience Multiple Channels Directed at Key XYOSTED® Targets Multi-channeling campaign targets physicians and patients through digital, social, enduring, and live platforms that drive awareness, prescription generation, and prescription fulfillment STEADYCare: Co-pay assistance for patients a

  14. Slide 14: Antares Pharma Partnered Products

    Antares Pharma Partnered Products March 2020

  15. Slide 15: Teva's Generic EpiPen

    Commercial Experience Teva’s Generic EpiPen Teva’s generic EpiPen® was approved by FDA as therapeutically equivalent to Mylan’s EpiPen® and is fully substitutable at the pharmacy Antares receives cost plus margin on all devices sold to Teva plus mid-to-high, single-digit royalties on in-market sales

  16. Slide 16: Teva's Generic EpiPen Quarterly TRx Prescription Trends

    Commercial Experience Teva’s Generic EpiPen® Quarterly TRx Prescription Trends Bloomberg/Symphony Health Solutions 448,471 506,086

  17. Slide 17: Makena hydroxyprogesterone caproate injection

    Commercial Experience Makena® hydroxyprogesterone caproate injection Makena® is to used to reduce the risk of pre-term birth in certain at-risk women Provides patients with efficient, discreet, and user-friendly administration AMAG/Antares collaboration began in 2014 Antares receives cost plus produ

  18. Slide 18: Antares Pharma Development Pipeline

    Antares Pharma Development Pipeline March 2020

  19. Slide 19: Global Development Agreement with Idorsia for Selatogrel

    Global Development Agreement with Idorsia for Selatogrel Antares entered into a global agreement with Idorsia Pharmaceuticals to develop a drug device product combining selatogrel, a New Chemical Entity - with the QuickShot Auto Injector Selatogrel is a fast acting and highly selective P2Y12 recepto

  20. Slide 20: Selatogrel: MI market and Phase II data

    Around 7.6 million Americans have survived an MI (Myocardial Infarction) Each year, around 750,000 have a new or recurrent MI1 550,000 have a first MI - 200,000 have a recurrent MI Product justification Onset of action of all oral P2Y12 inhibitors may be delayed by up to 6 hours or more in the setti

  21. Slide 21: Global Development Agreement With Idorsia For Selatogrel

    Global Development Agreement With Idorsia For Selatogrel Idorsia will pay for the development of the combination product and take responsibility for obtaining global regulatory approvals Antares and Idorsia intend to enter into a separate license and commercial supply agreement under which Antares w

  22. Slide 22: Generic Forteo (teriparatide)

    Teva continues to work with the FDA on their generic Forteo application* Teva has successfully completed a decentralized registration process in 17 countries in Europe and Canada and is waiting to launch globally According to Lilly’s 2019 reported results, Forteo® full year global revenues were $1.4

  23. Slide 23: Diversified Combination Products Portfolio

    Diversified Combination Products Portfolio

  24. Slide 24: Antares Pharma Q4 2019 Financial Results

    Antares Pharma Q4 2019 Financial Results March 2020

  25. Slide 25: Fourth Quarter and Full Year 2019 Financial Results

    Fourth Quarter and Full Year 2019 Financial Results Three Months Ended Dec 31 Increase Twelve Months Ended Dec 31 Increase 2019 2018 (Decrease) 2019 2018 (Decrease) Total Revenue $ 37,839 $ 18,821 101% $ 123,864 $ 63,554 95% Cost of Revenue 14,026 9,630 46% 50,475 31,065 62% Gross Profit 23,813 9,19

  26. Slide 26: 2020 Catalysts, Accomplishments, Foundation

    2020 Catalysts Accomplishments Foundation As a Pharmaceutical Technology Company, we Identify, develop, and commercialize important rescue and self-injection medicines Antares 2019: ‘A Transformational Year’ 2019 revenue of $123.9 million, a 95% increase over 2018 reported revenue Q4 2019 revenue of

  27. Slide 27: Thank you – Questions

    antares pharma Thank you Questions making medicines better fool

Antares Pharma — Investor Presentation (March 2020) on 6ix